Daiichi Sankyo Company, Limited

Shuichi Yada

Kazuhiro Yoshida

Hideki Yano

Atsutoshi Ito

Susumu Hasegawa

Sachiko Fukui

Ryoichi Hayakawa

Michiko Kumon

Tsuyoshi Nagaike

Misato Yokoi

Mitsuhide Tanimoto

An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides a pharmaceutical composition having abuse deterrent properties that possesses both a physical barrier and a chemical barrier to being abused by an abuser, a method for producing the same and a method for using the same.

Pharmaceutical composition having abuse deterrent properties

An object of the present invention is to provide a method for producing selectively a powder particle consisting of the &#x3b1;-form crystal of D-mannitol, using the spray-drying method. It is a method for selective production of powder particles consisting of the &#x3b1;-form crystal of D-mannitol, wherein a D-mannitol solution containing a water-soluble polymer is spray-dried.

Selective production method for D-mannitol &#x3b1;-form crystal using spray-drying method

An object is to provide a hydromorphone hydrochloride- or oxycodone hydrochloride hydrate-containing sustained-release pharmaceutical composition for oral administration that reliably exhibits its main pharmacological effect and has excellent formulation stability that avoids dose dumping of the principal drug, such as alcohol resistance. The present invention provides a sustained-release pharmaceutical composition comprising (A) hydromorphone hydrochloride or oxycodone hydrochloride hydrate, (B) hydroxypropyl methylcellulose acetate succinate having a median size (D) of 40 &#x3bc;m or smaller, (C) hydroxypropyl cellulose, and (D) a saccharide, wherein the content ratio of the component (C) to the component (B) by weight in the composition, (C)/(B), is 11/3 to 3/11.

Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition

A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using said composition is also provided.

Dissolution properties of drug products containing olmesartan medoxomil

Growing community of inventors

Fujisawa, Japan

Shuichi Yada